[go: up one dir, main page]

MX2025005240A - Métodos para el tratamiento de la nefritis lúpica mediante el uso de antagonistas de fcrn - Google Patents

Métodos para el tratamiento de la nefritis lúpica mediante el uso de antagonistas de fcrn

Info

Publication number
MX2025005240A
MX2025005240A MX2025005240A MX2025005240A MX2025005240A MX 2025005240 A MX2025005240 A MX 2025005240A MX 2025005240 A MX2025005240 A MX 2025005240A MX 2025005240 A MX2025005240 A MX 2025005240A MX 2025005240 A MX2025005240 A MX 2025005240A
Authority
MX
Mexico
Prior art keywords
lupus nephritis
methods
treating lupus
fcrn
fcrn antagonists
Prior art date
Application number
MX2025005240A
Other languages
English (en)
Inventor
Hauwermeiren Tim Van
Peter Verheesen
Magdalena Sips
Original Assignee
argenx BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by argenx BV filed Critical argenx BV
Publication of MX2025005240A publication Critical patent/MX2025005240A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se proporcionan métodos para tratar la nefritis lúpica mediante el uso de una cantidad eficaz de un antagonista del receptor de Fc neonatal (FcRn) humano. En la presente también se proporcionan antagonistas de FcRn para su uso en el tratamiento de la nefritis lúpica y para su uso en la elaboración de un medicamento para el tratamiento de la nefritis lúpica.
MX2025005240A 2022-11-07 2025-05-06 Métodos para el tratamiento de la nefritis lúpica mediante el uso de antagonistas de fcrn MX2025005240A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263382566P 2022-11-07 2022-11-07
PCT/IB2023/000679 WO2024100453A1 (en) 2022-11-07 2023-11-07 Methods for treating lupus nephritis using fcrn antagonists

Publications (1)

Publication Number Publication Date
MX2025005240A true MX2025005240A (es) 2025-08-01

Family

ID=89772263

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025005240A MX2025005240A (es) 2022-11-07 2025-05-06 Métodos para el tratamiento de la nefritis lúpica mediante el uso de antagonistas de fcrn

Country Status (11)

Country Link
US (1) US20250360207A1 (es)
EP (1) EP4615481A1 (es)
JP (1) JP2025537707A (es)
KR (1) KR20250109193A (es)
CN (1) CN120322244A (es)
AR (1) AR130994A1 (es)
AU (1) AU2023378498A1 (es)
IL (1) IL320700A (es)
MX (1) MX2025005240A (es)
TW (1) TW202421195A (es)
WO (1) WO2024100453A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3720877A1 (en) 2017-12-08 2020-10-14 Argenx BVBA Use of fcrn antagonists for treatment of generalized myasthenia gravis
AU2019283673B2 (en) 2018-06-08 2023-12-07 argenx BV Compositions and methods for treating immune thrombocytopenia
FI4087875T3 (fi) 2020-01-08 2024-10-25 argenx BV Vastasyntyneen ihmisen Fc-reseptorin (FcRn) antagonisteja pemfigus-häiriöiden hoitoon
AU2023291783A1 (en) 2022-06-15 2024-12-12 argenx BV Fcrn binding molecules and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56102A (fr) * 2019-06-07 2022-04-13 Argenx Bvba Formulations pharmaceutique d'inhibiteurs de fcrn appropriées pour une administration par voie sous-cutanée
AU2021376364A1 (en) * 2020-11-06 2023-06-22 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
AR128284A1 (es) * 2022-01-17 2024-04-10 argenx BV Métodos para tratar a pacientes con una enfermedad mediada por autoanticuerpos

Also Published As

Publication number Publication date
EP4615481A1 (en) 2025-09-17
KR20250109193A (ko) 2025-07-16
AR130994A1 (es) 2025-02-05
CN120322244A (zh) 2025-07-15
WO2024100453A1 (en) 2024-05-16
IL320700A (en) 2025-07-01
TW202421195A (zh) 2024-06-01
JP2025537707A (ja) 2025-11-20
AU2023378498A1 (en) 2025-04-24
US20250360207A1 (en) 2025-11-27

Similar Documents

Publication Publication Date Title
MX2025005240A (es) Métodos para el tratamiento de la nefritis lúpica mediante el uso de antagonistas de fcrn
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
Deer et al. The Polyanalgesic Consensus Conference (PACC): recommendations for trialing of intrathecal drug delivery infusion therapy
Kim et al. Low handgrip strength is associated with low bone mineral density and fragility fractures in postmenopausal healthy Korean women
Soin et al. High-frequency electrical nerve block for postamputation pain: a pilot study
SG148143A1 (en) Antagonist anti-cd40 monoclonal antibodies and methods for their use
MX2024013015A (es) Métodos para tratar penfigoide ampolloso con el uso de antagonistas de fcrn
PL4087875T3 (pl) Antagoniści ludzkiego noworodkowego receptora fc (fcrn) do leczenia zaburzeń pęcherzowych
MX2024001849A (es) Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita.
WO2021016571A3 (en) Methods of treating antibody-mediated disorders with fcrn antagonists
MX2021002556A (es) Tratamiento del dolor postquirurgico.
MX2025008040A (es) Métodos para tratar el síndrome de sjögren primario con el uso de antagonistas fcrn
CR9957A (es) Uso de un anatagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia
MX2022013174A (es) Semaglutida para el tratamiento de la esteatohepatitis no alcoholica.
MX2025002984A (es) Tratamiento de trastornos autoinmunitarios mediante terapia con receptor quimerico para el antigeno
Fang et al. Optimization of electrical stimulation for the treatment of lower limb dysfunction after stroke: A systematic review and Bayesian network meta-analysis of randomized controlled trials
MX2023013815A (es) Antagonista del ligando del cumulo de diferenciacion 40 (cd40l) y usos del mismo en el tratamiento de la nefritis lupica.
MX2023001199A (es) Antagonistas de receptor nk para pacientes con cancer.
MX2023009550A (es) Antagonistas del receptor del peptido-1 tipo glucagon.
WO2022093552A8 (en) Rev-erb agonists
Capó-Juan et al. Short term effectiveness of Pressure Release and Kinesiotaping in Cervical Myofascial Pain caused by sternocleidomastoid muscle: A randomized clinical trial
MX2022016410A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos.
MX2023006567A (es) Regimen de dosificacion para un nam del receptor nr2b-nmda para el tratamiento de la depresion.
WO2021262562A3 (en) Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof
MX2023003032A (es) Terapia de combinacion de un antagonista de pd-1 y un antagonista de lag3 y lenvatinib o una sal farmaceuticamente aceptable del mismo para el tratamiento de pacientes con cancer.